INNOVATION BY THE NUMBERS
A YEAR IN REVIEW

BREAKTHROUGH INVENTIONS*

3 U.S. DEVICE APPROVALS
FreeStyle® Libre Pro | Absorb™ | TECNIS®

>60 NEW BRANDED GENERIC PHARMACEUTICALS
in Latin America

5 NEW NUTRITIONALS
- Ensure® Enlive®
- EAS® Myoplex®
- EAS® Ketogenic
- Similac® Pro-Advance™
- Similac® Pro-Sensitive™

NEW DIAGNOSTICS SOLUTIONS
Alinity | Alinity®

INVESTMENT IN R&D AND MANUFACTURING*

>$3.5B INVESTMENT IN R&D,
U.S. MANUFACTURING AND INFRASTRUCTURE
since the beginning of 2014

NEW R&D FACILITIES
LAUNCHED IN CHINA AND BRAZIL

41 R&D SITES
WORLDWIDE IN
20 COUNTRIES

17 IN NORTH AMERICA
10 IN EUROPE
6 IN LATIN AMERICA
8 IN ASIA

R&D FOCUS

DIAGNOSTICS
Developing next-generation diagnostics tools

BRANDED GENERIC PHARMACEUTICALS
Offering affordable, high-quality, trusted medicines

MEDICAL DEVICES
Revolutionizing medical technology

NUTRITION
Developing science-based nutrition products

HISTORY OF INNOVATION

1925
Similac®, the first commercial milk-based baby formula by Abbott.

1932
Abbott discovers halibut livers have 20 times the vitamin D and 100% more vitamin A than cod liver in Pacific fishing excursions.

1943
Abbott introduces a way to mass produce penicillin, critical during World War II.

1985
Abbott scientists unveil the first licensed test to identify the HIV virus in blood.

1989
Abbott scientists unveil the first licensed test to identify the HIV virus in blood.

1989
Abbott launches Glucerna® for people with diabetes, pioneering a new category of disease-specific nutritional.

2010
The first stent to dissolve after clearing a blocked artery receives CE Mark approval in Europe. (2016 U.S. approval)

2014
FreeStyle® Libre**, our revolutionary glucose monitoring system, is approved in Europe. **under review in the U.S.

*For the year ended December 31, 2016.